Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-22
2010-06-15
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S220000
Reexamination Certificate
active
07737165
ABSTRACT:
A method of reducing weight gain associated with olanzapine treatment in a human subject, by orally administering to an olanzapine-treated subject betahistine or a salt thereof, is disclosed.
REFERENCES:
patent: 4159332 (1979-06-01), Bollenbacher
patent: 6620942 (2003-09-01), Yeh et al.
patent: 6649614 (2003-11-01), Carlson et al.
patent: 2003/0162824 (2003-08-01), Krul
patent: 2005/0222175 (2005-10-01), Dhanoa et al.
patent: 2006/0039867 (2006-02-01), Rao et al.
patent: 2006/0073217 (2006-04-01), Barak
patent: WO 00/38725 (2000-07-01), None
patent: WO 00/53162 (2000-09-01), None
patent: WO 2002/087556 (2002-11-01), None
patent: WO 2004/024094 (2004-03-01), None
patent: WO 2005/101979 (2005-03-01), None
Rossi et al., Physiology & Behavior, vol. 66, No. 3 (1999), pp. 517-521.
The Merck Index (1999) 17thedition, pp. 58-60.
The Merck Manual (1999), 17thedition, p. 1570.
Ito et al. “Toxicological and Teratological Studies on N-Methyl-N-?-(2-Pyridyl)-Ethylamine (Betahistine)”, Oyo Yakuri, 2(4): 344-348, 1968.
Fossati et al. “Binding Affinity Profile of Betahistine and Its Metabolites for Central Histamine Receptors of Rodents”, Pharmacological Research, 43(4): 389-392, 2001.
Hagan “Peptide YY: A Key Mediator of Orexigenic Behavior”, Peptides, 23: 377-382, 2002.
Poyurovsky et al. “The Effect of Betahistine, A Histamine H 1 Receptor Antagonist/H3 Antagonist, on Olanzapine-Induce Weight Gain in First-Episode Schizophrenia Patients”, International Clinical Psychopharmacology, 20: 101-103, 2005.
Kasaoka et al. “Histidine Supplementation Suppresses Food Intake and Fat Accumulation in Rats”, Nutrition, 20: 991-996, 2004.
Yoshimatsu et al. “Histidine Suppresses Food Intake Through Its Conversion Into Neuronal Histamine”, Experimental Biology and Medicine, 227(1): 63-68, 2002.
Baptista et al. “Drug Induced Weight Gain, An Impediment to Successful Pharmacotherapy: Focus on Antipsychotics”, Current Drug Targets, 5: 279-299, 2004.
Kane et al. “Metabolic Effects of Treatment With Atypical Antipsychotics”, Journal of Clinical Psychiatry, 65(11): 1447-1455, 2004.
Lieberman III “Metabolic Changes Associated With Antipsychotic Use”, Primary Care Companion—Journal of Clinical Psychiatry, 6(Suppl.2): 8-13, 2004.
Newcomer “Second-Generation (Atypical) Antipsychotics and Metabolic Effects”, CNS Drugs, 19(Suppl.1): 1-93, 2005.
Rasmussen et al. “Preclinical Pharmacology of FMPD [6-Fluoro-10-[3-(2-Methozyethyl)-4-Methyl-Piperazin-1-Y1]-2-Methyl-4H-3-Thia-4,9-Diaza-Benzo[f]Azulene]: A Potential Novel Antipsychotic With Lower Histamine H1 Receptor Affinity Than Olanzapine”, The Journal of Pharmacology and Experimental Therapeutics, 315(3): 1265-1277, 2005.
Wetterling “Bodyweight Gain With Atypical Antipsychotics”, Drug Safety, 24(1): 59-73, 2001.
Orthen-Gambill “Antihistaminic Drugs Increase Feeding, While Histidine Suppresses Fedding in Rats”, Pharmacology Biochemistry & Behavior, 31: 81-86, 1988.
Sakata et al. “Blockade of the histamine Hi-receptor in the rat ventromedial hypothalamus and feeding elicitation”,Brain Research, 441: 403-407, 1988.
Donna et al. “Schizophrenia and Obesity: Impact of Antipsychotic Medications”, Journal of Cliinical Psychiatry, 65(18): 13-26, 2004.
Masaki et al. “Central Infusion of Histamine Reduces Fat Accumulation and Upregulates UCP Family in Leptin-Resistant Obese Mice”, Diabetes, 50: 379-384, 2001.
Yoshimatsu et al. “Histamine Neurons Down-Regulate ob Gene Expression in Rat White Adipose Tissue”, Inflamm. res. 50, (Suppl 2): S72-S73, 2001.
Masaki et al. “Involvement of Hypothalamic Histamine H1 Receptor in the Regulation of Feeding Rhythm and Obesity”, Diabetes, 53, 2250-2260, 2004.
Rossi et al. “Effect of the H1-Histamine Receptor Agonist Betahistine on Drinking and Eating Behavior in Pygmy Goats”, Physiology & Behavior, 66(3): 517-521, 1999.
Szelag et al. “Betahistine Inhibits Food Intake in Rats”, Polish Journal of Pharmacology, 53: 701-707, 2001.
Abramof Ness et al. “Drug-Induced Weight Gain”, Drugs of Today, 41: 1-9, 2005.
Navarro-Badenes et al. “Weight Gain Associated With Cinnarizine”, Annuals in Pharmacotherapy, 26(7-8): 928-930,1992. Abstract.
Albera et al. “Double-Blind, Randomized, Multicenter Study Comparing the Effect of Betahistine and Flunarizine on the Dizziness Handicap in Patients With Recurrent Vestibular Vertigo”, Acta Otalaryngol, 123: 588-593, 2003.
Arrang et al. “Actions of Betahistine at Histamine Receptors in the Brain”, European Journal of Pharmacology, 111: 73-84, 1985.
Attoub et al. “The H3 Receptor Is Involved in Cholecystokinin Inhibition of Food Intake in Rats”, Life Sciences, 69: 469-478, 2001.
Barbarich et al. “An Open Trial of Olanzapine in Anorexia Nervosa”, Journal of Clinical Psychiatry, 65(11): 1480-1482, 2004.
Barrett et al. “Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes”, Journal of Clinical Psychiatry, 65(2): 267-272, 2004.
Bjenning et al. “OCFR and CFR (6-33) Depress Food But Not Water Intake in the Obese Zucker Rat”, International Journal of Obesity, 24(Suppl.2): S140-S141, 2000.
Bustillo et al. “Differential Effect of Clozapine on Weight: A Controlled Study”, The American Journal of Psychiatry, 153(6): 817-819, 1996.
Gordon et al. “Evaluation of Betahistine for the Prevention of Seasickness: Effect on Vestibular Function, Psychomotor Performance and Efficacy at Sea”, Journal of Vestibular Research, 13: 103-111, 2003.
Itoh et al. “Thioperamide, A Histamine H3 Receptor Antagonist, Powerfully Suppresses Peptide YY-Induced Food Intake in Rats”, Biological Psychiatry, 45: 475-481, 1999.
Onderwater et al. “Cytotoxicity of A Series of Mono- and Di-Substituted Thiourea in Freshly Isolated Rat Hepatocytes: A Preliminary Structure-Toxicity Relationship Study”, Toxicology, 125: 117-129, 1998.
Sakata et al. “Hypothalamic Neuronal Histamine: Implications of Its Homeostatic Control of Energy Metabolism”, Nutrition, 13: 403-411, 1997.
Seifert et al. “Multiple Differences in Agonist and Antagonist Pharmacology Between Human and Guinea Pig Histmaine H1-Receptor”, The Journal of Pharmacology and Experimental Therapeutics, 305(3): 1104-1115, 2003.
Seipel et al. “Rheoencephalographic and Other Studies of Betahsitine in Humans: I. The Cerebral and Peripheral Circulatory Effects of Single Doses in Normal Subjects”, The Journal of Clinical Pharmacology, p. 144-154, 1975.
Snyman et al. “The Influence of Betahistine on the Dynamics of the Cutaneous Hypersensitivity Reaction in Patients With Grass Pollen Allergy”, Immunopharmacology, 30: 71-78, 1995.
Theisen et al. “Spectrum of Binge Eating Symptomatology in Patients Treated With Clozapine and Olanzapine”, Journal of Neural Transmission, 110: 111-121, 2003.
Wirshing et al. “Novel Antipsychotics: Comparison of Weight Gain Liabilities”, Journal of Clinical Psychiatry, 60(6): 358-363, 1999.
Wirshing “Schizophrenia and Obesity: Impact of Antipsychotic Medications”, Journal of Clinical Psychiatry, 65(Suppl.18): 13-26, 2004.
Lecklin et al. “Inhibition of Histamine Catabolism Suppresses Fat Intake But Not the Intake of Carbohydrates and Protein”, Inflammation Research, 51(Suppl.1): S53-S54, 2002.
Lecklin et al. “Effects of Intracerebroventricularly Infused Histamine and Selective H1, H2 and H3 Agonists on Food and Water Intake and Urine Flow in Wistar Rats”, Brain Research, 793: 279-288, 1998.
Leurs et al. “Therapeutic Potential of Histamine H3 Receptor Agonists and Antagonists”, Trends in Pharmacological Sciences, TiPS, 19: 177-184, 1998.
Lean et al. “Patients on Atypica
Mor Research Applications Ltd.
Spivack Phyllis G.
LandOfFree
Methods of reducing weight gain associated with olanzapine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of reducing weight gain associated with olanzapine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing weight gain associated with olanzapine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181119